In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion
- 99 Downloads
CT-P6 is a biosimilar of trastuzumab, a monoclonal antibody targeting human epidermal growth factor 2 (HER2), that is used in the treatment of breast and gastric cancers.
The aim of this study was to evaluate the in-use physicochemical and biological stability of CT-P6 following preparation for intravenous (IV) infusion.
One batch of CT-P6 within the final month of its 48-month shelf life was used to simulate sub-optimal administration conditions. CT-P6 dilutions of 0.4, 1.0, and 4.0 mg/mL, representative of actual use scenarios, were prepared in 0.9% saline solution in either polypropylene (PP) or polyvinylchloride (PVC) infusion bags. Following refrigeration at 2–8 °C for 1 month, samples were incubated at room temperature for 24 h. Physicochemical and biological stability were evaluated according to presence of sub-visible particles, pH, proportion of molecular weight variants, oxidation level of methionine residues 107, 255/256 and 432/433, and binding affinity to the Fc neonatal receptor and HER2.
Analyses of CT-P6 preparations at all concentrations tested and in both PP and PVC infusion bags revealed no changes in sub-visible particles, pH, molecular weight variants, oxidation, or potency after 1 month at 2–8 °C followed by exposure to room temperature for 24 h.
These analyses demonstrate the extended stability, after refrigerated storage for 1 month followed by 24-h exposure to room temperature, of CT-P6 under the dilution conditions required for IV infusion. This stability was sustained for all dilution factors and both infusion bag materials tested.
Medical writing support (including development of a first and subsequent drafts in consultation with the authors, assembling tables and figures, collating author comments, copyediting, fact checking, and referencing) was provided by Emma Prest, PhD at Aspire Scientific (Bollington, UK) and was funded by Celltrion Healthcare Co., Ltd. (Incheon, Republic of Korea). Drafts were reviewed by Sang-Wook Yoon, PhD and Dasom Choi at Celltrion Healthcare Co., Ltd.
Compliance with Ethical Standards
This study was sponsored by Celltrion, Inc.
Conflict of interest
All authors are employees of Celltrion, Inc. The authors have no other conflicts of interest related to this work.
SJK and JWL were involved in the conception and design of this study. SJK, JWL, HYK, SYK, YKS, KWK, JSO, KJL, and JYK were involved in the acquisition, analysis, and/or interpretation of the data. SJK, JWL, HYK, SYK, YKS, KWK, JSO, KJL, and JYK developed the manuscript and approved the final version for submission.
- 3.United States Food and Drug Administration. Herceptin prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf. Accessed 17 April 2018.
- 4.European Medicines Agency. Herzuma. Summary of opinion. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002575/WC500240426.pdf. Accessed 17 April 2018.
- 5.European Medicines Agency. Herzuma. Summary of product characteristics. 2018. https://ec.europa.eu/health/documents/community-register/2018/20180209139854/anx_139854_en.pdf. Accessed 17 April 2018.
- 8.International Conference on Harmonization Guideline. Stability testing of new drug substances and products Q1A(R2). 2003. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf. Accessed 19 April 2018.
- 9.International Conference on Harmonization Guideline. Stability testing of biotechnological/biological products Q5C. 1995. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf. Accessed 19 April 2018.
- 11.Kaiser J, Kramer I. Physicochemical stability of diluted trastuzumab infusion solutions in polypropylene infusion bags. Int J Pharm Compd. 2011;15(6):515–20.Google Scholar
- 12.European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substances: quality issues (revision 1). 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf. Accessed 19 April 2018.
- 13.Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. 2015. https://www.fda.gov/downloads/drugs/guidances/ucm291134.pdf. Accessed 19 April 2018.
- 14.European Medicines Agency. Note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution. 1998. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003476.pdf. Accessed 18 April 2018.
- 20.European Pharmacopoeia 6.0. 2.9.19. Particulate contamination: sub-visible particles. 2008. http://www.uspbpep.com/ep60/2.9.19.%20particulate%20contamination-%20sub-visible%20particles%2020919e.pdf. Accessed 17 Apr 2018.